assigned to the control group had higher risk of CVD as compared to those with lower 23 levels of acylcarnitines assigned to the MedDiet group.
24
Conclusions: Our data support that metabolite profiles characterized by elevated 25 concentrations of acylcarnitines are independently associated with the risk of total CVD 26 and stroke alone in participants at high cardiovascular risk. MedDiet interventions may 27 mitigate the adverse associations found between higher concentrations of acylcarnitines 28 and CVD.
29
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31
BACKGROUND
32
Cardiovascular disease (CVD) is the leading cause of death and disability in 33 industrialized countries (1) . Although many cardiovascular risk factors, such as smoking, 34 obesity, diabetes, and poor dietary habits have been identified (2) , the understanding of 35 CVD etiology and its mechanisms is still incomplete. More comprehensive approaches 36 may help to deepen our knowledge of CVD physiopathology, and also identify patients 37 at high risk -potentially years before diagnosis-that will benefit most from preventive 38 strategies. Thus, emerging high-throughput metabolomics has been proposed as one of 39 the novel and useful tools for the early diagnosis of metabolic diseases (3, 4) .
40
Among several metabolites identified as potential keys to metabolic diseases, 41 acylcarnitines, which are intermediates of fatty acid oxidation, have been associated 42 with CVD risk (5) (6) (7) (8) . Elevated concentrations of these metabolites may be indicative of 43 impaired β-oxidation and mitochondrial dysfunction (5) , and have been associated with 44 higher risk of obesity, insulin resistance and type 2 diabetes (9,10), all recognized risk 45 factors of CVD. To date, only few studies have examined the associations between 46 acylcarnitines and CVD, and these studies had small sample sizes and were conducted 47 only in patients with established coronary heart disease. Also, they included no or 48 scarce information on diet and lifestyles (5) (6) (7) (8) . The association between acylcarnitines 49 and CVD, and in particular changes in their concentrations, in the context of primary 50 cardiovascular prevention remains therefore to be elucidated.
51
Importantly, a Western dietary pattern was associated with a specific metabolite 52 signature characterized by increased levels of short-chain acylcarnitines (11) , and some 53 dietary components have been shown to change the acylcarnitine metabolite profile in 54 8 plasma or other fluids and tissues (12) (13) (14) (15) . However, whether the potential association 55 between acylcarnitines and CVD risk is modified by an intervention with an overall 56 healthy dietary pattern such as the Mediterranean diet has not yet been investigated.
57
In the present prospective nested case-cohort study, we performed quantitative 58 profiling of 28 acylcarnitine species in plasma samples of elderly participants at high 59 cardiovascular risk from the PREDIMED trial. We hypothesized that higher 60 concentrations at baseline and 1-year changes in acylcarnitine concentrations would be 61 associated with the risk of CVD and that these associations might be modified by a
62
Mediterranean Diet (MedDiet) intervention. Our aim was to determine the association of 
METHODS
68
Study population
69
The design and protocol of the PREDIMED study (http://www.predimed.es) have 70 been described in detail elsewhere (16, 17) . In brief, the PREDIMED study was a large, 
85
We designed a case-cohort study in the framework of the PREDIMED trial (18) . A case-86 cohort study design dictates that all cases and a randomly selected percentage of the 87 original cohort (referred to as the "subcohort," which by its random selection may 88 therefore include some cases) are selected as participants. In the context of a trial, the 89 case-cohort study design allows us to: 1) maintain the trial's original randomization scheme; 2) limit the randomly selected subcohort to fewer participants than the entire 91 cohort for cost savings; and 3) extrapolate the results to all the participants in the study.
92
In keeping with the study design, from the eligible cohort participants with available follow-up. We defined "subcohort" as the random sample selected from the full roster of 102 the PREDIMED study (including some incident CVD cases). We defined "internal cases" 103 as the cases that were randomly included in this random subcohort. We defined 104 "external cases" as the cases that weren't randomly included in the subcohort. All 105 participants provided written informed consent according to a protocol approved by the 106 institutional review boards prior to inclusion in the study.
108
Metabolite profiling
109
At baseline and at yearly follow-up visits, trained nurses collected fasting blood 110 samples from the PREDIMED participants. After an overnight fast, tubes for EDTA 111 plasma were collected and aliquots were coded and kept refrigerated until they were stored at -80°C freezers. Pairs of samples (baseline and first-year visit) were randomly 113 ordered and shipped on dry ice to the Broad Institute for the metabolomics analysis.
114
Amino acids, acylcarnitines, and other polar plasma metabolites were profiled using to-face interviews with participants (21) . We used Spanish food composition tables to 163 estimate energy and nutrient intake (22) . Trained personnel took anthropometric and 164 blood pressure measurements.
165
Statistics
166
We applied an inverse normal transformation to approximate a normal 
207
We repeated the analysis using incident stroke as the outcome, both including 208 and excluding the non-stroke CVD cases (i.e., treating the 113 non-stroke CVD cases 209 as non-cases, or removing them from analyses), and found similar results. Therefore,
210
we present stroke results only after removing the non-stroke CVD cases.
211
To assess the effect of the MedDiet interventions, we introduced a multiplicative group as a single group vs. the control group). We stratified the analysis described 215 above by intervention group (both MedDiet interventions vs. control). We conducted 216 joint analyses for both the baseline and 1-year changes in acylcarnitine scores and the 217 intervention group using as the reference group participants assigned to the MedDiet 218 group and with lower baseline levels of acylcarnitines (quartile 1 of the three scores).
219
Finally, we compared the adjusted mean changes in the individual metabolites from 220 baseline to 1 year by intervention group, using the same models as described above.
221
All statistical analyses were performed using SAS (v9.4, SAS Institute, Cary, NC) 222 and R (v2.13.0, R Foundation, Vienna, Austria). A P value <0.05 was considered
RESULTS
225
Baseline characteristics of the 980 individuals (229 cases and 751 non-cases) 226 included in the present case-cohort study are described in The associations between baseline acylcarnitine scores and the risk of CVD are 234 presented in Table 2 . Across all models in the overall study population, higher risk of scores and stroke were found for those individuals assigned to MedDiet interventions.
266
Results for further adjustment of multivariable model 2 for total energy intake and a 267 branched-chain amino acids score were consistent with the primary analysis and 268 resulted in higher risk of CVD for short, medium and long-chain acylcarnitine scores.
269
Per SD increase in short-chain acylcarnitines the HR (95% CI) was 2.43 (1.49, 3.97), for medium-chain acylcarnitines: 1.51 (1.02, 2.24), and for long-chain acylcarnitine score: 
DISCUSSION
307
In this prospective case-cohort study of individuals at high cardiovascular risk, we 308 found that a baseline profile of increased short-chain and medium-chain plasma 309 acylcarnitines was associated with higher risk of CVD independent of established 310 cardiovascular risk factors. We also identified elevated concentrations of short-chain 311 acylcarnitines as potential biomarkers of future stroke risk. These metabolites were 312 altered up to 3-4 years before the onset of CVD. We also observed that 1-year changes 313 in short-chain and long-chain acylcarnitine scores were directly associated with an 314 increased risk of both total CVD and stroke alone, independent of baseline levels of 315 these metabolites and recognized risk factors of CVD. Participants with higher levels of 316 short-and medium-chain acylcarnitines at baseline and who were assigned to the 317 control group had a higher risk of both total CVD and stroke alone, suggesting that Acylcarnitines are derived from both fatty acid and amino acid β-oxidation (27) .
390
They can be formed from almost any CoA ester. Acylcarnitines can also be derived from 391 other intermediates such as ketone bodies, degradation products of lysine, tryptophan, 392 valine, leucine, isoleucine and carbon atoms from glucose (28) . The main function of L-393 carnitine is to transport fatty acids from the cytosol to the mitochondrial matrix, where β-394 oxidation takes place, this process results in the esterification of L-carnitine to form 395 acylcarnitine derivatives (29) . Acylcarnitines can be measured in plasma after being 396 transported across cell membranes (27) . Accumulation of acylcarnitines may be 397 indicative of inefficient β-oxidation and altered mitochondrial metabolism (8) . These processes are enhanced in the aging process, in particular, advanced age leads to 
405
The main limitation of the present study is that our results may not be A: short-chain acylcarnitines: C2carnitine, C3DCCH3carnitine, C3carnitine,
